Records containing: Stage IIIB Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-06-05A Phase I Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN144) With Adjuvant Pembrolizumab for Treatment of Immunotherapy Naïve Patients With High Risk Stage IIIb-dResectable Melanoma
-
CLINICAL_TRIALS study record update · 2023-06-18A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma
-
CLINICAL_TRIALS study record update · 2021-01-20Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2020-01-02Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2019-08-08A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2018-10-09Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study
-
CLINICAL_TRIALS study record update · 2018-07-03A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401
-
CLINICAL_TRIALS study record update · 2018-05-09Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2017-06-23Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma
-
CLINICAL_TRIALS study record update · 2017-04-13FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2017-02-20A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a >1mm Melanoma on Initial Biopsy
-
CLINICAL_TRIALS study record update · 2016-08-03A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2015-07-23Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases
-
CLINICAL_TRIALS study record update · 2015-04-15A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Resected Stages IIB/C, III And IV Melanoma
-
CLINICAL_TRIALS study record update · 2014-12-23A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT
-
CLINICAL_TRIALS study record update · 2014-09-25Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib
-
CLINICAL_TRIALS study record update · 2014-06-18A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on Prior Therapy With a Selective BRAF Inhibitor (i.e., Vemurafenib, Dabrafenib, LGX818)
-
CLINICAL_TRIALS study record update · 2014-05-22A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA
-
CLINICAL_TRIALS study record update · 2014-01-20A Phase 2 Study of Dasatinib in Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2013-01-31A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma